[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-371396-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-371396-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","acute-myeloid-leukemia-mitochondria-hydrolyze-atp-to-support-oxidative-metabolism-and-resist-chemotherapy","Acute myeloid leukemia mitochondria hydrolyze ATP to support oxidative metabolism and resist chemotherapy","","Oxidative phosphorylation (OxPhos) inhibitors face limited clinical benefit because they cannot reliably distinguish healthy from cancerous mitochondria. This work describes an actionable bioenergetic mechanism unique to acute myeloid leukemia (AML) mitochondria: AML mitochondria consume ATP to sustain inner-membrane polarization under bioenergetic stress. The study proposes that AML cells may resist chemotherapy by reversing the ATP synthase reaction, supported by venetoclax-related findings, ATP5IF1 regulation, and chemotherapy resistance outcomes.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/acute-myeloid-leukemia-mitochondria-hydrolyze-atp-to-support-oxidative-metabolism-and-resist-chemotherapy/371396/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/acute-myeloid-leukemia-mitochondria-hydrolyze-atp-to-support-oxidative-metabolism-and-resist-chemotherapy/371396.png","ImageObject",300,407,{"name":42,"@type":43},"Valentina","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-28","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why have OxPhos inhibitors struggled to show clinical benefit in AML?","Question",{"text":63,"@type":64},"They have difficulty distinguishing healthy mitochondria from cancerous mitochondria, limiting therapeutic selectivity and effectiveness.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What bioenergetic mechanism is proposed as unique to AML mitochondria?",{"text":68,"@type":64},"AML mitochondria support inner-membrane polarization by consuming ATP, enabling survival under bioenergetic stress.",{"name":70,"@type":61,"acceptedAnswer":71},"How is mitochondrial ATP consumption linked to chemotherapy resistance in AML cells?",{"text":72,"@type":64},"The study hypothesizes that AML cells resist chemotherapy-induced death by reversing the ATP synthase reaction, with venetoclax-related experiments and ATP5IF1 regulation supporting this link.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},371396,1790220788,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","CANCER  \nAcute myeloid leukemia mitochondria hydrolyze ATP to support oxidative metabolism and resist chemotherapy  \nJames T. Hagen1,2, McLane M. Montgomery1,2,3, Raphael T. Aruleba3, Brett R. Chrest3,  \nPolina Krassovskaia3, Thomas D. Green3, Emely A. Pacheco3, Miki Kassai2, Tonya N. Zeczycki4, Cameron A. Schmidt2,5, Debajit Bhowmick6, Su-Fern Tan7,8, David J. Feith7,8,  \nCharles E. Chalfant7,8,9,10, Thomas P. Loughran Jr.7,8, Darla Liles11, Mark D. Minden12, Aaron D. Schimmer12, Md Salman Shakil13,14, Matthew J. McBride13,14, Myles C. Cabot2,4, Joseph M. McClung15, Kelsey H. Fisher-Wellman3*  \nOxPhos inhibitors have struggled to show a clinical benefit because of their inability to distinguish healthy from cancerous mitochondria. Herein, we describe an actionable bioenergetic mechanism unique to acute myeloid leukemia (AML) mitochondria. Unlike healthy cells that couple respiration to ATP synthesis, AML mitochondria support inner-membrane polarization by consuming ATP. Matrix ATP consumption allows cells to survive bioenergetic stress. Thus, we hypothesized AML cells may resist chemotherapy-induced cell death by reversing the ATP synthase reaction. In support, BCL-2 inhibition with venetoclax abolished OxPhos flux without affecting mitochondrial polarization. In surviving AML cells, sustained mitochondrial polarization depended on matrix ATP consumption. Mitochondrial ATP consumption was further enhanced in AML cells made refractory to venetoclax, consequential to down-regulations in the endogenous F1-ATPase inhibitor ATP5IF1. Knockdown of ATP5IF1 conferred venetoclax resistance, while ATP5IF1 overexpression impaired F1-ATPase activity and heightened sensitivity to venetoclax. These data identify matrix ATP consumption as a cancer cell–intrinsic bioenergetic vulnerability actionable in the context of BCL-2 targeted chemotherapy.  \ncopyright © 2025 the Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. no claim to original U.S.  \nGovernment Works. distributed under a creative commons Attribution license 4.0 (cc BY) .  \nINTRODUCTION  \nSimilar to a growing list of human solid organ malignancies, acute myeloid leukemia (AML) is particularly reliant on oxidative metabolism ( 1–7). Pioneering studies over the past several years have repeatedly demonstrated potent antileukemic effects upon targeting AML’s mitochondrial reliance (8–16) . Although mitochondrial targeted therapies are entering clinical trials, most hopeful “mitotherapeutics” suffer from a limited therapeutic index based on their inability to discriminate cancerous from noncancerous mitochondria (16–20) . The lack of cancer-specific mitochondrial targets poses a barrier to progress, as safe and effective mitochondrial-targeted therapies will likely require cancer cell selectivity. Fortunately, new evidence is emerging that all mitochondria are not alike. Mitochondria are unique in composition and function within each cell type, including AML cells (16–19, 21–24). This raises the exciting possibility that identifying the unique bioenergetic signature(s) of AML cells  \n1department of Physiology, Brody School of Medicine, east carolina University, Greenville, nc, USA. 2east carolina diabetes and Obesity institute, east carolina University, Greenville, nc, USA. 3department of cancer Biology, Atrium Health Wake Forest Baptist comprehensive cancer, Wake Forest University School of Medicine, Winston-Salem, nc, USA. 4department of Biochemistry and Molecular Biology, Brody School of Medicine, east carolina University, Greenville, nc, USA. 5department of Biology, east carolina University, Greenville, nc, USA. 6Brody School of Medicine at east carolina University, Flow cytometry core, Greenville, nc, USA. 7department of Medicine, Hematology/Oncology, University of virginia School of Medicine, charlottesville, vA, USA. 8University of virginia cancer center, charlottesville, vA, USA. 9department of cell Biology, University of virg","cbCaiglPJQEKGx0P","https://ap.wps.com/l/cbCaiglPJQEKGx0P","pdf",9101878,23,"English","# Introduction\n## Mitochondrial dependence in AML\n## Limitations of current mitotherapeutics\n## Chemoresistant AML bioenergetics and mitochondrial polarization","[{\"question\":\"Why have OxPhos inhibitors struggled to show clinical benefit in AML?\",\"answer\":\"They have difficulty distinguishing healthy mitochondria from cancerous mitochondria, limiting therapeutic selectivity and effectiveness.\"},{\"question\":\"What bioenergetic mechanism is proposed as unique to AML mitochondria?\",\"answer\":\"AML mitochondria support inner-membrane polarization by consuming ATP, enabling survival under bioenergetic stress.\"},{\"question\":\"How is mitochondrial ATP consumption linked to chemotherapy resistance in AML cells?\",\"answer\":\"The study hypothesizes that AML cells resist chemotherapy-induced death by reversing the ATP synthase reaction, with venetoclax-related experiments and ATP5IF1 regulation supporting this link.\"}]","Acute myeloid leukemia mitochondria hydrolyze ATP to support oxidative metabolism and resist chemotherapy | PDF",1790191978,58,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/86c9643ec8c25b53a27963fc1593adc8.webp",983,1250,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e249a2f50a52dbb711b7794303c0a969.webp",982,1249,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/61e37dba698d0a4a9030c3940b1be17e.webp",981,1248,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2d36ae1d692035f8385373cabc86dab5.webp",980,1247]